Onco Actu du 17 mars 2020

	4.2 DÉP., DIAG. & PRONO. - GÉNOME
DNA tests grow more vital in hereditary breast cancer treatments. They also raise unanswerable questions. [Washington Post] Amid the enthusiasm for widespread testing for breast cancer patients, however, some doctors and genetic counselors are worried about how to handle the windfall of genetic information these new tests provide.
	4.9 DÉP., DIAG. & PRONO. - SEIN
Aging Out of the Mammogram [NY Times] For many women, regular breast cancer screening is standard medical protocol. But for older women, should it be?
	5.1 TRAITEMENTS - PRÉ-CLINIQUE
Cancer Drug with Better Staying Power and Reduced Toxicity Shows Promise in Preclinical Trials [University of Texas] The drug candidate, called OxaliTEX, is made of two parts: a star-shaped molecule called texaphyrin that acts like a kind of delivery truck, and a modified version of a platinum drug that acts like a toxic package for cancer cells.
	5.12.5 IMMUNOTHÉRAPIES - PHARMA
Imfinzi confirmed a sustained overall survival benefit in final analysis of the Phase III CASPIAN trial in 1st-line extensive-stage small cell lung cancer [AstraZeneca] A second immunotherapy, tremelimumab, added to Imfinzi, did not meet its primary endpoint of overall survival.
AstraZeneca's lung cancer treatment fails to meet main goal [Reuters] Earlier this month, Imfinzi and tremelimumab as a combo treatment for a form of bladder cancer also failed to meet the main goal of a late-stage study.
	5.12.8 IMMUNOTHÉRAPIES - ECONOMIE
Merck's Keytruda pulled from England's Cancer Drugs Fund in bladder cancer [Fierce Pharma] The decision is particularly disappointing for Keytruda and patients because Keytruda was was the only med among its rivals to score even a Cancer Drugs Fund recommendation in the indication. Roche’s Tecentriq and BMS’ Opdivo each were rejected in bladder cancer in earlier NICE decisions.
	5.2.3 PHARMA - ÉCONOMIE
How are pharma supply chains reacting to COVID-19? Without info, it's hard to tell: analyst [Fierce Pharma] The novel coronavirus is putting pharma's complicated global supply chain under strain, no question. What's up in the air is just how supplies could be affected––and unfortunately, analysts just can't be sure.
	6.7.2 APPLIS
App Detects Harsh Side Effect of Breast Cancer Treatment [Georgia Tech] The advantages of the new technology over perometers are cost and convenience. Perimeters are bulky, costly machines, while the LymphaTech system runs on iPhone or iPad and requires only a $400 camera attachment and a paid smartphone app. Both devices simply determine total volume of the arm for swelling diagnosis.